Chronic lymphocytic leukaemia

Michael Hallek, Tait D. Shanafelt, Barbara Eichhorst

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management.

Original languageEnglish (US)
Pages (from-to)1524-1537
Number of pages14
JournalThe Lancet
Volume391
Issue number10129
DOIs
StatePublished - Apr 14 2018
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Standard of Care
Disease Management
Developed Countries
Leukemia
Phosphotransferases
Therapeutics
Monoclonal Antibodies
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hallek, M., Shanafelt, T. D., & Eichhorst, B. (2018). Chronic lymphocytic leukaemia. The Lancet, 391(10129), 1524-1537. https://doi.org/10.1016/S0140-6736(18)30422-7

Chronic lymphocytic leukaemia. / Hallek, Michael; Shanafelt, Tait D.; Eichhorst, Barbara.

In: The Lancet, Vol. 391, No. 10129, 14.04.2018, p. 1524-1537.

Research output: Contribution to journalReview article

Hallek, M, Shanafelt, TD & Eichhorst, B 2018, 'Chronic lymphocytic leukaemia', The Lancet, vol. 391, no. 10129, pp. 1524-1537. https://doi.org/10.1016/S0140-6736(18)30422-7
Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. The Lancet. 2018 Apr 14;391(10129):1524-1537. https://doi.org/10.1016/S0140-6736(18)30422-7
Hallek, Michael ; Shanafelt, Tait D. ; Eichhorst, Barbara. / Chronic lymphocytic leukaemia. In: The Lancet. 2018 ; Vol. 391, No. 10129. pp. 1524-1537.
@article{9894351ec0254bdeace53ac5eda0832c,
title = "Chronic lymphocytic leukaemia",
abstract = "Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management.",
author = "Michael Hallek and Shanafelt, {Tait D.} and Barbara Eichhorst",
year = "2018",
month = "4",
day = "14",
doi = "10.1016/S0140-6736(18)30422-7",
language = "English (US)",
volume = "391",
pages = "1524--1537",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "10129",

}

TY - JOUR

T1 - Chronic lymphocytic leukaemia

AU - Hallek, Michael

AU - Shanafelt, Tait D.

AU - Eichhorst, Barbara

PY - 2018/4/14

Y1 - 2018/4/14

N2 - Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management.

AB - Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management.

UR - http://www.scopus.com/inward/record.url?scp=85045269675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045269675&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(18)30422-7

DO - 10.1016/S0140-6736(18)30422-7

M3 - Review article

AN - SCOPUS:85045269675

VL - 391

SP - 1524

EP - 1537

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10129

ER -